Frontiers in Cardiovascular Medicine

NOVEMBER 19, 2024

We recorded several key outcomes, including early and late intervention-related complications, the need for reintervention, the interval between the NP and the first intervention, shunt patency following the intervention, associated morbidities, and thrombosis-related sudden events. kg), respectively.

Thrombosis 59

Thrombosis Stents Stent Congenital Heart Disease 59

Stroke: Vascular and Interventional Neurology

NOVEMBER 9, 2023

XIENCE Skypoint™ stent was deployed within the left vertebral artery (V4 segment) with restoration of flow preceded by eptifibatide drip (Fig 2). Repeat CTA at six months showed patent left vertebral and basilar arteries.ConclusionRescue stenting using DES may be a successful and safe therapeutic intervention for challenging failed MT.

Stents 40

Stents Stent Thrombosis Thrombolysis 40

Stroke: Vascular and Interventional Neurology

NOVEMBER 9, 2023

In order to improve treatment outcomes in these difficult cases, the use of stent‐assisted embolization has been attempted in endovascular treatment of intracranial aneurysms. Thromboembolic complications were observed in one patient, with the clinical outcome of death due to basilar stent thrombosis.

Aneurysm 40

Aneurysm Stents Stent Hemorrhage 40

Circulation

NOVEMBER 23, 2023

3.30]) and subacute definite or probable stent thrombosis (0.58% and 0.17%; hazard ratio, 3.40 [95% CI, 1.26–9.23]) years; men, 76.6%; acute coronary syndrome, 75.0%). There was no difference in net adverse clinical outcomes and each component of coprimary cardiovascular end point.

Stents 40

Stents Stent Thrombosis Myocardial Infarction 40

DAIC

SEPTEMBER 10, 2024

"Clinicians need better tools to guide decision making on the choice of antiplatelet therapy in coronary artery disease patients, particularly after coronary stenting. The Prolocor pFCG test will be an important asset as we tailor antiplatelet therapies to balance thrombotic and bleeding risk" said Dominick J.

Thrombosis 52

Thrombosis Coronary Artery Disease Innovation Stents 52

Circulation

OCTOBER 24, 2023

Background:Stopping aspirin within 1 month after implantation of a drug-eluting stent (DES) for ticagrelor monotherapy has not been exclusively evaluated for patients with acute coronary syndrome (ACS). Circulation, Ahead of Print. versus 3.4%; HR, 0.35 [95% CI, 0.20–0.61];P<0.001).Conclusions:This 0.61];P<0.001).Conclusions:This

Stents 40

Stents Stent Myocardial Infarction Thrombosis 40

Circulation

NOVEMBER 11, 2024

The outcome was any 30-day event defined as death, stent thrombosis, major bleeding events, and composites of ischemic and bleeding events. Two stent thrombosis events occurred, both in patients receiving dual antithrombotic therapy with clopidogrel (P=0.09).

Thrombosis 40

Thrombosis Outcomes Stents Stent 40

Open Heart

OCTOBER 26, 2022

Background Bioresorbable vascular scaffolds (BVS) were designed to reduce the rate of late adverse events observed in conventional drug-eluting stents (DES) by dissolving once they have restored lasting patency.

Stents 52

Stents Stent Coronary Artery Disease Myocardial Infarction 52

Cardiovascular Diabetology

DECEMBER 7, 2023

Subjects with type 2 diabetes (T2D) have a higher risk of in-stent restenosis and stent thrombosis. The activation of the glucagon-like peptide-1 receptor (GLP-1R) has been suggested to induce several effects.

Diabetes 64

Diabetes Thrombosis Stents Stent 64

The British Journal of Cardiology

NOVEMBER 10, 2023

The near-immediate or instant feedback learning process by which the heart responds to any new invasive procedural variation facilitates each new change; be it drug-eluting stent, drug-coated balloon, or both in different combinations and permutations.

Stents 40

Stents Stent Coronary Artery Disease Myocardial Infarction 40

Journal of the American Heart Association

JANUARY 12, 2024

Journal of the American Heart Association, Ahead of Print.

Thrombosis 40

Thrombosis Stents Stent 40

Heart BMJ

NOVEMBER 27, 2023

(Charles Darwin) Despite being proposed more than three decades ago, dual antiplatelet therapy has become a cornerstone of medical treatment for patients suffering from acute coronary syndrome after the introduction of bare metal stents to overcome the risk of restenosis and stent thrombosis associated with such devices.

Thrombosis 40

Thrombosis Stents Stent 40

The British Journal of Cardiology

OCTOBER 8, 2024

That, it was possible to treat atherosclerotic coronary artery disease with an updated Andreas Grüntzig’s balloon alone, without the safety net and comfort of implanting a single stent. Three interactive cases were treated with the drug-coated balloon and all patients were same-day discharged.

Coronary Artery Disease 52

Coronary Artery Disease Stents Stent Hospital 52

The American Journal of Cardiology

JULY 18, 2024

Publication date: Available online 17 July 2024 Source: The American Journal of Cardiology Author(s): Gani Bajraktari, Ibadete Bytyçi, Genc Abdyli, Pranvera Ibrahimi, Artan Bajraktari, Rona Karahoda, Shpend Elezi, Michael Y.

Thrombosis 52

Thrombosis Stents Stent 52

Dr. Smith's ECG Blog

NOVEMBER 14, 2024

History of diabetes type II and stent placement in 2018. Here it is: Obvious inferior OMI, and now the STE in V1 is huge, with huge hyperacute T-waves of Right ventricular OMI The cath lab was re-activated: Angiogram: 100% occlusion mid-RCA occlusion (in-stent thrombosis). What do you think? I responded: "Definite inferior OMI.

Academic 120

Academic Stents Stent Thrombosis 120

Frontiers in Cardiovascular Medicine

JUNE 5, 2024

BackgroundBehcet's disease (BD) is a systematic vasculitis that affects vessels with various sizes, presenting as venous thrombosis and arterial pseudoaneurysms.

Embolism 52

Embolism Aortic Thrombosis Stents 52

Circulation

FEBRUARY 12, 2024

The secondary outcomes included ischemia-driven target lesion revascularization, target vessel myocardial infarction, death, cardiac death, target vessel revascularization, stent thrombosis, and major adverse cardiac events. OCT was associated with a significant reduction of stent thrombosis compared with ICA (OR, 0.49 [95% CI, 0.26–0.92])

Ultrasound 67

Ultrasound Myocardial Infarction Thrombosis Stents 67

Heart BMJ

AUGUST 14, 2024

Previous medical interventions included a spectrum of procedures, including catheter-directed thrombectomy for popliteal artery aneurysms with thrombosis, vascular bypass grafting for cerebral-anterior communicating artery aneurysms and arch replacement and stent implantation for aortic dissecting aneurysms.

Aneurysm 52

Aneurysm Chest Pain Myocardial Infarction Thrombosis 52

CardiacWire

MARCH 2, 2024

The United States has been way behind other nations in using drug-coated balloons (DCB) to treat coronary in-stent restenosis (ISR), but that’s about to change thanks to the FDA approval of Boston Scientific’s AGENT Drug-Coated Balloon. vs 12.3%) Stent thrombosis (0.0% vs. 24.0%) Target vessel myocardial infarction (6.4%

Angioplasty 59

Angioplasty Stents Stent Myocardial Infarction 59

DAIC

NOVEMBER 8, 2024

In the DA+DCB arm, there was a trend toward higher stent-free patency through 12 months (79.1% versus 68.1%, · P=0.09) and a significantly lower provisional stenting rate (9.5% 3,4 bailout stenting rates were low following atherectomy in both observational studies (9.3% versus 21.1%, P =0.014). 3 · One-year rates of TLR (16.6%

Stents 52

Stents Stent Angioplasty Peripheral Arterial Disease 52

Stroke: Vascular and Interventional Neurology

OCTOBER 2, 2023

BackgroundProcedural intravenous cangrelor has been proposed as an effective platelet inhibition strategy for stenting in acute ischemic stroke. Safety outcomes included rates of symptomatic intracranial hemorrhage, parenchymal hematoma type 2, petechial hemorrhage, and in‐stent thrombosis. 3.28];P=0.836). versus 0%;P=0.911).ConclusionCangrelor

Hemorrhage 40

Hemorrhage Thrombosis Stents Stent 40

Journal of the American Heart Association

JANUARY 12, 2024

0.71];P<0.001), stent thrombosis (RR, 0.63 [95% CI, 0.40–0.99];P=0.046), ConclusionsIn patients undergoing PCI, intravascular imaging is associated with reductions in major adverse cardiac events, cardiac death, stent thrombosis, target‐lesion revascularization, and target‐vessel revascularization.

Thrombosis 45

Thrombosis Stents Stent Outcomes 45

Open Heart

JANUARY 6, 2022

These results were driven mainly by the reduction in repeat vessel revascularisation, stroke and stent thrombosis. Conclusion Colchicine significantly reduced the risk of MACE in patients with CAD who underwent PCI, mostly in the reduction of repeat vessel revascularisation, stroke and stent thrombosis.

Coronary Artery Disease 52

Coronary Artery Disease Thrombosis Stents Stent 52

Frontiers in Cardiovascular Medicine

FEBRUARY 5, 2024

Anaphylaxis leads to plaque rupture or erosion leading to acute myocardial infarction (type II) and acute coronary stent thrombosis (type III). Here we share a case of Kounis syndrome type I caused by an allergy caused by a Cryptopteran bite.

Coronary Artery Disease 64

Coronary Artery Disease Electrocardiogram Myocardial Infarction Thrombosis 64

All About Cardiovascular System and Disorders

APRIL 21, 2024

If the FFR normalizes after stenting, the restenosis rates at six months is less than 5%. Since the FFR wire can be used for guiding balloon catheters and stents, it is easy to make post procedure measurements without any additional effort. Routine FFR measurement probably lead to more judicious use of stents and improved outcomes.

Myocardial Infarction 52

Myocardial Infarction Coronary Artery Disease Stents Stent 52

Frontiers in Cardiovascular Medicine

NOVEMBER 21, 2024

There were no surgery-related deaths, no paraplegia,and all patients were successfully discharged.

Aortic 52

Aortic Thrombosis Aneurysm Stents 52

Frontiers in Cardiovascular Medicine

JANUARY 30, 2024

Overall, 27/36 procedures were interventional, including 6 aortic valvuloplasties, 6 balloon angioplasties, and 15 stenting procedures. Results We identified 30 patients (66.7% males) with a median age of 1.1 months (IQR, 0.3–5.4), 5.4), and a median weight of 3.1 kg kg (IQR, 2.7–3.7). months (IQR, 1.7–5.1). mm (IQR, 2.4–3). min (IQR, 19.2–34.8).

Pediatrics 49

Pediatrics Congenital Heart Disease Thrombosis Angioplasty 49

Coronary Artery Disease Journal

AUGUST 22, 2024

Data were extracted from published reports and quality assessment was performed per Cochrane recommendations. Statistical analysis was performed using Review Manager (Cochrane collaboration).

Myocardial Infarction 40

Myocardial Infarction Thrombosis Stents Stent 40

Journal of Cardiovascular Pharmacology

MAY 2, 2024

The primary outcome was major adverse cardiac and cerebrovascular event (MACCE), namely a composite of death from cardiovascular causes, myocardial infarction (MI), stroke, stent thrombosis within 12 month. The secondary outcome was Bleeding Academic Research Consortium (BARC) scale bleeding events within 12 months.

Outcomes 40

Outcomes Myocardial Infarction Thrombosis Academic 40

Frontiers in Cardiovascular Medicine

MARCH 10, 2024

5.11), repeat PCI or stent thrombosis (pooled RR 1.99, 95% CI 1.21–3.28), In subsequent analyses, admission hyperglycemia was associated with an increased risk of reinfarction (pooled RR 1.69, 95% CI 1.31–2.17), 2.17), heart failure (pooled RR 1.56, 95% CI: 1.37–1.77), 1.77), cardiogenic shock (pooled RR 3.68, 95% CI 2.65–5.11),

Myocardial Infarction 59

Myocardial Infarction Cardiogenic Shock Article Outcomes 59

Circulation

NOVEMBER 11, 2024

Introduction:Subacute stent thrombosis (ST) is related to high rates of cardiac reinfarction. Circulation, Volume 150, Issue Suppl_1 , Page A4137144-A4137144, November 12, 2024. We present a case of reinfarction from ST.

Chest Pain 40

Chest Pain Coronary Artery Disease Angioplasty Thrombosis 40

Circulation

NOVEMBER 11, 2024

vs 13.6%), any stent thrombosis (RR=1.42; 95% CI [0.35, 5.72]; p=0.62; 2.2% The pooled results of the 4 RCTs showed that MACE (RR=0.66; 95% CI [0.45, 0.99]; p=0.01; 16.8% vs 24.1%), PCI revascularization (RR=0.50; 95% CI [0.37, 0.67]; p<0.00001; 13.1% vs 6.0%), stroke (RR=1.02; 95% CI [0.38, 2.75]; p =0.97; 2.0%

Coronary Artery Disease 40

Coronary Artery Disease Myocardial Infarction STEMI Thrombosis 40

Stroke: Vascular and Interventional Neurology

NOVEMBER 9, 2023

Follow‐up data including aneurysm thromboembolic complication, hemorrhagic complication, new neurological deficit, aneurysm occlusion, and in‐stent thrombosis were also recorded.ResultsOne‐hundred and eighty patients were included in analysis, 18 of which were acutely ruptured.

Embolism 40

Embolism Aneurysm Hemorrhage Stents 40

Coronary Artery Disease Journal

MARCH 7, 2024

Similarly, all-cause mortality, cardiovascular mortality, stent thrombosis, and acute renal insufficiency did not show significant differences between two groups.

Myocardial Infarction 40

Myocardial Infarction Ischemia Thrombosis Article 40

Open Heart

DECEMBER 29, 2022

There was also no difference in the rate of bleeding between PFT-guided and standard therapies (major bleeding: RR=0.97, p=0.78, minor bleeding: RR=0.89, p=0.19 and any bleeding: RR=1.04, p=0.33).

Myocardial Infarction 52

Myocardial Infarction Thrombosis Stents Stent 52

Circulation

FEBRUARY 26, 2024

The primary efficacy objective was to demonstrate superiority of PPA to reduce the primary efficacy end point of all-cause death, nonfatal myocardial infarction, nonfatal stroke, stent thrombosis (definite), or urgent revascularization (any vessel) within 30 days.

Myocardial Infarction 40

Myocardial Infarction Academic Thrombosis STEMI 40

Journal of Cardiovascular Pharmacology

NOVEMBER 6, 2023

Primary endpoint of systematic review and meta-analysis is the NACE (Net Adverse Cardiac Events) and secondary are MACE (Major Adverse Cardiac Events), mortality, bleedings, myocardial infarction and stent thrombosis. Subgroup analyses included studies using only ticagrelor-based regimens and three-months duration of DAPT.

Diabetes 40

Diabetes Myocardial Infarction Thrombosis Stents 40